Evaluation some immune aspects in Iraqi women patients with breast cancer
Main Article Content
Keywords
breast cancer, Naturall killer cells, dendritic cells,CD56,CD1a.
Abstract
The current experiment have been conducted to to determinate the activity of natural killer cells of CD56 and dendritic cells of CD1a by estimating the expression for both markers depending on flow cytometery technique . Blood samples are taken from 60 patients women with breast cancer to represent patients group and 40 women’s without breast cancer to represent control group, the ages of both groups ranged from 30 to more than 50 years in the Al.Diwaniyah General Teaching Hospital in AL-Qadisyaha province .
Also ROC curve analyzed is used to demonstrate the accuracy and validity of previous parameters in detecting women with breast cancer and to estimate the sensitivity and specificity.
The results of this study show that the patients group have recorded highly significant (p<0.01) superiority in natural killer cells of CD56 (23.780) comparison with control group which is (10.708 ) , in addition to the patients group have appeared significant increase in dendritic cells of CD1a on control group by 5.741. .
Age groups have showed significant (p<0.05)effect on natural killer cells of CD56 , there is decline in natural killer cells of CD56 with age progress, while the decline in dendritic cells of CD1a with age progress do not reach to significant level .
Analysis of ROC curve for CD56 and CD1a has been showed that these characters are excellent indicators to detecting actually patients with breast cancer,the sensevity and specificity for CD56 and CD1a is 90.90,20 and 25% respectively. The cut-off for CD56 and CD1a is more 11.85 and more than 2.65 respectively.
References
1. Agrawal, A., & Gupta, S. (2011). Impact of aging on dendritic cell functions in humans. Ageing research reviews, 10(3), 336-345.
2. Bendall, SC.; Nolan, GP.; Roederer, M. and Chattopadhyay, PK. (2012). A deep profiler‟s
guide to cytometry. Trends Immunol. , 33: 323 332.
3. Benvidi, A., Dehghani Firouzabadi, A., Dehghan Tezerjani, M., Moshtaghiun, S. M., Mazloum-Ardakani, M., & Ansarin, A. (2015). A highly sensitive and selective electrochemical DNAbiosensor to diagnose breast cancer. Journal of Electroanalytical Chemistry, 750, 57–64.
4. Boivin, W. A., Cooper, D. M., Hiebert, P. R., & Granville, D. J. (2009). Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Laboratory investigation, 89(11), 1195-1220.Breen N, Gentleman JF, Schiller JS. (2011). Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer; 117: 2209- 2218.
5. Castle, S. C. (2000). Clinical relevance of age-related immune dysfunction. Clinical Infectious Diseases, 31(2), 578-585.
6. Cavallaro, S., Paratore, S., de Snoo, F., Salomone, E., Villari, L., Buscarino, C., Ferraù, F., Banna, G., Furci, M., Strazzanti, A., Cunsolo, R., Pezzino, S., Gangi, S.and Basile, F. (2012 ). Genomic analysis: toward a new approach in breast cancer management. Crit. Rev. Oncol. Hematol., 81: 207-223
7. Cernadas, M., Lu, J., Watts, G., & Brenner, M. B. (2009). CD1a expression defines an interleukin-12 producing population of human dendritic cells. Clinical & Experimental Immunology, 155(3), 523-533.
8. Chidrawar, S. M., Khan, N., Chan, Y. L., Nayak, L., & Moss, P. A. (2006). Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immunity & Ageing, 3(1), 1-8.
9. Coventry BJ, Lee PL, Gibbs D, Hart DN (2002) Dendritic cell density and activation status in human breast cancer –CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer 86: 546 – 551
10. Coventry, B. J., Weeks, S. C., Heckford, S. E., Sykes, P. J., Bradley, J., & Skinner, J. M. (1996). Lack of IL-2 cytokine expression despite Il-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers. The Journal of Immunology, 156(9), 3486-3492.
11. Fujimoto, Y., & Tedder, T. F. (2006). CD83: a regulatory molecule of the immune system with great potential for therapeutic application. Journal of medical and dental sciences, 53(2), 85-91.
12. Heravi Karimovi, M., Pourdehqan, M., Jadid Milani, M., Foroutan, S. K., & Aieen, F. (2006). Study of the effects of group counseling on quality of sexual life of patients with breast cancer under chemotherapy at Imam Khomeini Hospital. Journal of mazandaran university of medical sciences, 16(54), 43-51.
13. Hillenbrand, E. E., Neville, A. M., & Coventry, B. J. (1999). Immunohistochemical localization of CD1a-positive putative dendritic cells in human breast tumours. British journal of cancer, 79(5), 940-944.
14. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer statistics, 2009. CA: a cancer journal for clinicians, 59(4), 225-249.
15. Klingemann, H. G. (2013). Cellular therapy of cancer with natural killer cells—where do we stand?. Cytotherapy, 15(10), 1185-1194.
16. Lanier, L. L. (2005). NK cell recognition. Annu. Rev. Immunol., 23, 225-274.
17. Liu, K., & Nussenzweig, M. C. (2010). Origin and development of dendritic cells. Immunological reviews, 234(1), 45-54.
18. Makdissi, F. B. A., Santos, S. S., Bitencourt, A., & Campos, F. A. B. (2022). An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations. International braz j urol, 48, 760-770. 19. Poli, A., Michel, T., Thérésine, M., Andrès, E., Hentges, F., & Zimmer, J. (2009). CD56bright natural killer (NK) cells: an important NK cell subset. Immunology, 126(4), 458-465.
20. Reichert, T. E., Scheuer, C., Day, R., Wagner, W., & Whiteside, T. L. (2001). The number of intratumoral dendritic cells and ζ‐chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society, 91(11), 2136-2147.
21. Roberti, M. P., Mordoh, J., & Levy, E. M. (2012). Biological role of NK cells and immunotherapeutic approaches in breast cancer. Frontiers in Immunology, 3, 375.
22. Robertson, M. J., Caligiuri, M. A., Manley, T. J., Levine, H. E. R. B. E. R. T., & Ritz, J. E. R. O. M. E. (1990). Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. Journal of immunology (Baltimore, Md.: 1950), 145(10), 3194-3201.Romagne F, Vivier E. Natural killer cell-based therapies. F1000 Med Rep 2011; 3: 9.
23. Sato, C., & Kitajima, K. (2021). Polysialylation and disease. Molecular Aspects of Medicine, 79, 100892.
24. Sisirak, V., Faget, J., Gobert, M., Goutagny, N., Vey, N., Treilleux, I., ... & Bendriss-Vermare, N. (2012). Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer ProgressionpDC in Breast Cancer Pathophysiology. Cancer research, 72(20), 5188-5197.
25. Soerjomataram, I., & Bray, F. (2021). Planning for tomorrow: Global cancer incidence and the role of prevention 2020–2070. Nature reviews Clinical oncology, 18(10), 663-672.
26. Spss,(2013).statistical pachage of social science.version22,aplication Guide:copy Right by spss Inc.USA.
27. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.
28. Szpor, J., Streb, J., Glajcar, A., Frączek, P., Winiarska, A., Tyrak, K. E., ... & Hodorowicz-Zaniewska, D. (2021). Dendritic cells are associated with prognosis and survival in breast cancer. Diagnostics, 11(4), 702.
29. Taouk, G., Hussein, O., Zekak, M., Abouelghar, A., Al-Sarraj, Y., Abdelalim, E. M., & Karam, M. (2019). CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse. Scientific reports, 9(1), 8756.
30. Treilleux, I., Blay, J. Y., Bendriss-Vermare, N., Ray-Coquard, I., Bachelot, T., Guastalla, J. P., ... & Lebecque, S. (2004). Dendritic cell infiltration and prognosis of early stage breast
cancer. Clinical Cancer Research, 10(22), 7466-7474.
31. Van Acker, H. H., Capsomidis, A., Smits, E. L., & Van Tendeloo, V. F. (2017). CD56 in the immune system: more than a marker for cytotoxicity?. Frontiers in immunology, 8, 892.
32. World Health Organization ,2020.Estimated of the new cases in 2020,worldwide .New Global Cancer Data.(WHO,2020).
33. Zamai, L., Ahmad, M., Bennett, I. M., Azzoni, L., Alnemri, E. S., & Perussia, B. (1998). Natural killer (NK) cell–mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. The Journal of experimental medicine, 188(12), 2375-2380.
34. Zweignd,M.H.,campbell.G.(1993).Receiver-operating characteristic (ROC) plots : a fundamental evaluation tooin clinical medicine .clinical chemistry.,39:561-577.
2. Bendall, SC.; Nolan, GP.; Roederer, M. and Chattopadhyay, PK. (2012). A deep profiler‟s
guide to cytometry. Trends Immunol. , 33: 323 332.
3. Benvidi, A., Dehghani Firouzabadi, A., Dehghan Tezerjani, M., Moshtaghiun, S. M., Mazloum-Ardakani, M., & Ansarin, A. (2015). A highly sensitive and selective electrochemical DNAbiosensor to diagnose breast cancer. Journal of Electroanalytical Chemistry, 750, 57–64.
4. Boivin, W. A., Cooper, D. M., Hiebert, P. R., & Granville, D. J. (2009). Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Laboratory investigation, 89(11), 1195-1220.Breen N, Gentleman JF, Schiller JS. (2011). Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer; 117: 2209- 2218.
5. Castle, S. C. (2000). Clinical relevance of age-related immune dysfunction. Clinical Infectious Diseases, 31(2), 578-585.
6. Cavallaro, S., Paratore, S., de Snoo, F., Salomone, E., Villari, L., Buscarino, C., Ferraù, F., Banna, G., Furci, M., Strazzanti, A., Cunsolo, R., Pezzino, S., Gangi, S.and Basile, F. (2012 ). Genomic analysis: toward a new approach in breast cancer management. Crit. Rev. Oncol. Hematol., 81: 207-223
7. Cernadas, M., Lu, J., Watts, G., & Brenner, M. B. (2009). CD1a expression defines an interleukin-12 producing population of human dendritic cells. Clinical & Experimental Immunology, 155(3), 523-533.
8. Chidrawar, S. M., Khan, N., Chan, Y. L., Nayak, L., & Moss, P. A. (2006). Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immunity & Ageing, 3(1), 1-8.
9. Coventry BJ, Lee PL, Gibbs D, Hart DN (2002) Dendritic cell density and activation status in human breast cancer –CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer 86: 546 – 551
10. Coventry, B. J., Weeks, S. C., Heckford, S. E., Sykes, P. J., Bradley, J., & Skinner, J. M. (1996). Lack of IL-2 cytokine expression despite Il-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers. The Journal of Immunology, 156(9), 3486-3492.
11. Fujimoto, Y., & Tedder, T. F. (2006). CD83: a regulatory molecule of the immune system with great potential for therapeutic application. Journal of medical and dental sciences, 53(2), 85-91.
12. Heravi Karimovi, M., Pourdehqan, M., Jadid Milani, M., Foroutan, S. K., & Aieen, F. (2006). Study of the effects of group counseling on quality of sexual life of patients with breast cancer under chemotherapy at Imam Khomeini Hospital. Journal of mazandaran university of medical sciences, 16(54), 43-51.
13. Hillenbrand, E. E., Neville, A. M., & Coventry, B. J. (1999). Immunohistochemical localization of CD1a-positive putative dendritic cells in human breast tumours. British journal of cancer, 79(5), 940-944.
14. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer statistics, 2009. CA: a cancer journal for clinicians, 59(4), 225-249.
15. Klingemann, H. G. (2013). Cellular therapy of cancer with natural killer cells—where do we stand?. Cytotherapy, 15(10), 1185-1194.
16. Lanier, L. L. (2005). NK cell recognition. Annu. Rev. Immunol., 23, 225-274.
17. Liu, K., & Nussenzweig, M. C. (2010). Origin and development of dendritic cells. Immunological reviews, 234(1), 45-54.
18. Makdissi, F. B. A., Santos, S. S., Bitencourt, A., & Campos, F. A. B. (2022). An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations. International braz j urol, 48, 760-770. 19. Poli, A., Michel, T., Thérésine, M., Andrès, E., Hentges, F., & Zimmer, J. (2009). CD56bright natural killer (NK) cells: an important NK cell subset. Immunology, 126(4), 458-465.
20. Reichert, T. E., Scheuer, C., Day, R., Wagner, W., & Whiteside, T. L. (2001). The number of intratumoral dendritic cells and ζ‐chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society, 91(11), 2136-2147.
21. Roberti, M. P., Mordoh, J., & Levy, E. M. (2012). Biological role of NK cells and immunotherapeutic approaches in breast cancer. Frontiers in Immunology, 3, 375.
22. Robertson, M. J., Caligiuri, M. A., Manley, T. J., Levine, H. E. R. B. E. R. T., & Ritz, J. E. R. O. M. E. (1990). Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. Journal of immunology (Baltimore, Md.: 1950), 145(10), 3194-3201.Romagne F, Vivier E. Natural killer cell-based therapies. F1000 Med Rep 2011; 3: 9.
23. Sato, C., & Kitajima, K. (2021). Polysialylation and disease. Molecular Aspects of Medicine, 79, 100892.
24. Sisirak, V., Faget, J., Gobert, M., Goutagny, N., Vey, N., Treilleux, I., ... & Bendriss-Vermare, N. (2012). Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer ProgressionpDC in Breast Cancer Pathophysiology. Cancer research, 72(20), 5188-5197.
25. Soerjomataram, I., & Bray, F. (2021). Planning for tomorrow: Global cancer incidence and the role of prevention 2020–2070. Nature reviews Clinical oncology, 18(10), 663-672.
26. Spss,(2013).statistical pachage of social science.version22,aplication Guide:copy Right by spss Inc.USA.
27. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.
28. Szpor, J., Streb, J., Glajcar, A., Frączek, P., Winiarska, A., Tyrak, K. E., ... & Hodorowicz-Zaniewska, D. (2021). Dendritic cells are associated with prognosis and survival in breast cancer. Diagnostics, 11(4), 702.
29. Taouk, G., Hussein, O., Zekak, M., Abouelghar, A., Al-Sarraj, Y., Abdelalim, E. M., & Karam, M. (2019). CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse. Scientific reports, 9(1), 8756.
30. Treilleux, I., Blay, J. Y., Bendriss-Vermare, N., Ray-Coquard, I., Bachelot, T., Guastalla, J. P., ... & Lebecque, S. (2004). Dendritic cell infiltration and prognosis of early stage breast
cancer. Clinical Cancer Research, 10(22), 7466-7474.
31. Van Acker, H. H., Capsomidis, A., Smits, E. L., & Van Tendeloo, V. F. (2017). CD56 in the immune system: more than a marker for cytotoxicity?. Frontiers in immunology, 8, 892.
32. World Health Organization ,2020.Estimated of the new cases in 2020,worldwide .New Global Cancer Data.(WHO,2020).
33. Zamai, L., Ahmad, M., Bennett, I. M., Azzoni, L., Alnemri, E. S., & Perussia, B. (1998). Natural killer (NK) cell–mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. The Journal of experimental medicine, 188(12), 2375-2380.
34. Zweignd,M.H.,campbell.G.(1993).Receiver-operating characteristic (ROC) plots : a fundamental evaluation tooin clinical medicine .clinical chemistry.,39:561-577.
Article Sidebar
Published
Jun 4, 2023
Article Details
How to Cite
Israa Allawi Luaibi Al-Hraishawi, Ziad M. Alkhozai, & Hadeel Jabar Neama Almuoswi. (2023). Evaluation some immune aspects in Iraqi women patients with breast cancer. Journal of Population Therapeutics and Clinical Pharmacology, 30(13), 315-323. https://doi.org/10.47750/jptcp.2023.30.13.031
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Israa Allawi Luaibi Al-Hraishawi, Ziad M. Alkhozai, & Hadeel Jabar Neama Almuoswi. (2023). Evaluation some immune aspects in Iraqi women patients with breast cancer. Journal of Population Therapeutics and Clinical Pharmacology, 30(13), 315-323. https://doi.org/10.47750/jptcp.2023.30.13.031